Depression Drugs Market
Depression Drugs Market Analysis By Drug Type (Generic Depression Drugs, Branded Depression Drugs), By Drug Class (Serotonin-norepinephrine Reuptake Inhibitors), By Disease (Major Depressive Disorder, Generalized Anxiety Disorder), By Distribution Channel - Regional Forecast 2031
Analysis of Depression Drugs market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Depression Drugs Market Outlook
The global depression drugs market reached a valuation of around US$ 13 Bn in 2020, which amounts to close to 50% share of the psychotropic drugs market.
| Depression Drugs Market Size (2020) | US$ 13 Bn |
| Sales Forecast for Depression Drugs (2031) | US$ 20 Bn |
| Global Market Growth Rate (2021 to 2031) | 4% CAGR |
| Share of Top 5 Depression Drug Manufacturers | 40% |
Sales of depression drugs are slated to accelerate at a CAGR of 4% to top US$ 20 Bn by 2031. Demand for serotonin-norepinephrine reuptake inhibitors (SNRIs), which hold the highest market share, is set to increase at a CAGR of 2% across the assessment period of 2021 to 2031.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Consumption Analysis of Depression Drugs (2016-2020) Vs Market Outlook (2021 to 2031)
As per Fact.MR, a market research and competitive intelligence provider, the global market for depression drugs was valued at US$ 13 Bn in 2020.
According to the World Health Organization (WHO), depression is one of the primary causes of disability, affecting more than 350 Mn people worldwide. Major factors driving growth of the depression medications market are the rising prevalence of mental diseases such as social anxiety and depression and increasing demand for serotonin-norepinephrine reuptake inhibitors (SNRIs).
Discovery of innovative approaches for development of tricyclic antidepressants with minimum side effects and long-term results, together with rising acceptance of new treatments, is expected to propel market expansion over the coming years.
Government measures to make basic treatment for all mental health issues more accessible will help the market expansion. Furthermore, rising concern about the disease condition and essential therapeutic demands, increase in the number of people suffering from stress, and rising sales of CNS stimulants are driving the market growth.
Latest trends of depression drugs, the presence of top distributors of antidepressants, and growing sales of selective serotonin reuptake inhibitors (SSRIs) are driving the market growth.
All of these factors are expected to drive the market at 4% CAGR across 2021 to 2031.
How are Research & Development Activities Fueling Depression Drug Sales?
Traditional depression-managing medications and treatments have a low success rate, with just 40% of patients reportedly recovering. These concerns have driven academics, scientists, and medication makers to look for novel approaches to improve the efficacy of major depressive disorder treatments.
Over the last few years, advances in the neuroscience of depression have opened up new anxiety disorders and depression treatment options. Moreover, market players are actively focusing on the development of novel non-pharmacologic and pharmacologic therapies in the existing mental health drugs market.
Growing demand for tricyclic antidepressants, rising sales of selective serotonin reuptake inhibitors (SSRIs), and increasing use of antidepressants are driving the market growth.
Several international research projects are increasingly assisting in the creation of new pharmaceuticals, treatments, and cures. The overall growth of the depression medicines market is likely to be influenced by research and development initiatives.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Will Side Effects of Depression Drugs Create Reluctance among Patients?
Depression medications lose their efficacy after a few months or years since the brain becomes less responsive to such drugs. As a result, the normal brain functions begin to hamper.
Symptoms such as blurred vision, vivid dreams, insomnia, fatigue, dizziness, and loss of coordination are observed by the patients who discontinue the intake of antidepressants. These after-effects caused by depression medications are anticipated to limit the growth of the global depression medicines market.
Which is the Most Profitable Regional Market for Depression Drug Manufacturers?
North America is likely to be a major revenue-generating region. Revenue from the North American regional market is projected to expand 1.3X by 2031.
North America constitutes the largest share of the global antidepressant market, given the high concentration of established market players who are focusing on enhancing the efficiency of mental health drugs.
Rise in awareness pertaining to anxiety disorders and depression treatment created by mental healthcare organizations, growing online sales of CNS stimulants, and increasing adoption of depression medications are expected to drive growth of the market in this region.
Country-wise Analysis
What is the Demand Outlook for Depression Drugs in the U.S.?
The U.S. market for depression drugs is expected to increase 1.5X by 2031. In the United States, the geriatric population is growing, which is likely to open up additional chances for market players.
According to the Anxiety and Depression Association of America's Facts and Statistics., anxiety disorder is among the most prevalent mental illnesses in the United States, affecting around 40 Mn American adults each year, or 18.1% of the total population of the country.
In addition, more than 16.1 million persons in the United States suffer from severe depressive illness each year, with women having a higher prevalence than males.
As a result, growing frequency of illnesses, the rising rate of antidepressant consumption, and the presence of depression drug manufacturers are projected to fuel the market growth in the U.S. over the forecast period.
How Lucrative is the Market for Depression Drugs in China?
Increasing R&D investments by government and market participants, development of novel medications for anxiety and depression-related diseases, and increasing demand for branded antidepressants are expected to drive the market expansion in China.
The market in China is expanding due to rising sales of atypical antipsychotics among adults, growing demand for serotonin antagonist and reuptake inhibitors, and increasing frequency of depressive syndromes among the younger population.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Category-wise Insights
Why are Serotonin-norepinephrine Reuptake Inhibitors (SNRIs) in Such High Demand?
Serotonin-norepinephrine reuptake inhibitors (SNRIs) is expected to contribute the largest share in the market. Sales of SNRIs are expected to increase 2X over the forecast period.
Low levels of serotonin and norepinephrine are linked to depression. These are neurotransmitters, or chemical messengers, which have been shown to have an impact on mood. Serotonin-norepinephrine reuptake inhibitors are a category of antidepressants that work by inhibiting the reuptake of serotonin and norepinephrine by nerves.
While these medications are often thought of as a group of interconnected antidepressants based on reuptake inhibition, their chemical structures and pharmacological effects range significantly.
Patients with anxiety and depressive disorders are treated with SNRIs as a second-line medication. Growing applications in the treatment of abnormal psychological alterations with improved efficacy will boost the demand for serotonin-norepinephrine reuptake inhibitors. These medications have also been shown to be useful in the treatment of long-term nerve discomfort in anxiety disorders.
How is Rising Incidence of Major Depressive Disorders among Populations Driving Market Growth?
Major depressive disorder has been envisaged to account for the most substantial share in the depression drugs market based on disease type. Major depressive disorder is the leading cause of market growth since the majority of people are diagnosed with this disorder as a result of increased stress levels.
The biological, psychological, and social sources of sadness are all possible causes of major depressive disorder. Family history, substantial life changes, particular medications, chronic health conditions, and substance abuse are all key risk factors.
According to the Substance Abuse and Mental Health Services Association, adolescents aged 12 to 17 years old had the greatest prevalence of major depressive disorder (MDD), followed by adults aged 18 to 25 years old.
Growing prevalence of major depressive disorder as well as rising awareness regarding depression therapy and management among the younger population is driving the growth of the antidepressant drugs market.
COVID-19 Impact on Depression Drug Demand and Sales
The COVID-19 pandemic is predicted to have an impact on the general expansion of the depression medications industry since a growing number of people suffering from mental illnesses are turning to prescription drugs like benzodiazepines and antidepressants.
Furthermore, as a precautionary measure to prevent the spread of the novel coronavirus, governments in various countries have instituted lockdowns, the demand for antianxiety drugs has increased significantly.
As a result, the antidepressant drugs market is likely to have a large impact during the COVID-19 crisis, given the rising incidence of depression and anxiety among the global population as a result of the pandemic.
The number of antidepressant prescriptions increased significantly in the first two quarters of 2020, and this trend is expected to continue in the post-pandemic era.
Competitive Landscape
Top manufacturers in the depression drugs market are adopting sustainable growth strategies to diversify their product portfolio, sustain their position in the global market, intensify their customer base, and garner share in the global depression medicines market.
- In June 2021, Nippon Chemiphar Co., Ltd and Sumitomo Dainippon Pharma Co., Ltd announced a joint R&D agreement as well as an agreement for the clinical study of the novel antidepressant candidate NC-2800.
Depression Drugs Industry Report Scope
| Attribute | Details |
| Forecast Period | 2021-2031 |
| Historical Data Available for | 2016-2020 |
| Market Analysis | Value in US$ Mn |
| Key Regions Covered |
|
| Key Countries Covered |
|
| Key Market Segments Covered |
|
| Key Companies Profiled |
|
| Pricing | Available upon Request |
Key Segments in Depression Drugs Industry Research
-
Drug Type
- Generic Depression Drugs
- Branded Depression Drugs
-
Drug Class
- Serotonin-norepinephrine Reuptake Inhibitors (SNRIs)
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Atypical Antipsychotics
- Central Nervous System (CNS) Stimulants
- Tricyclic Antidepressants
- Monoamine Oxidase Inhibitors
-
Disease Type
- Depression Drugs for Major Depressive Disorder
- Depression Drugs for Obsessive-Compulsive Disorder
- Depression Drugs for Generalized Anxiety Disorder
- Depression Drugs for Panic Disorder
- Depression Drugs for Schizophrenia
- Depression Drugs for Bipolar 1 Disorder
-
Distribution Channel
- Sales of Depression Drugs via Hospital Pharmacies
- Sales of Depression Drugs via Retail Pharmacies
- Sales of Depression Drugs via Online Pharmacies
Table of Content
1. Preface 1.1. Market Segmentation 1.2. Key Research Objectives 1.3. Research Highlights 2. Assumptions and Acronyms Used 3. Research Approach & Methodology 3.1. Research Methodology overview 3.2. Project Initiation 3.3. Secondary Research Methodology 3.4. Primary Research Methodology 3.5. Analysis Research Methodology 3.6. Final Report & Conclusions Research Methodology 4. Executive Summary: Global Depression Drugs Market 5. Market Overview 5.1. Overview 5.2. Key Industry Events and Developments 5.3. Global Depression Drugs Market Forecast and Analysis 5.4. Global Depression Drugs Market Outlook 6. Market Dynamics 6.1. Drivers and Restraints Snapshot Analysis 6.2. Drivers 6.3. Restraints 6.4. Opportunities 6.5. Key Trends 6.6. Pipeline Analysis 6.7. Depression Treatment Market Value Chain Analysis 7. Global Depression Drugs Market, by Drug Class 7.1. Introduction & Definition 7.2. Key Findings / Developments 7.3. Global Depression Drugs Market, by Drug Class 7.3.1. Atypical antipsychotics 7.3.2. Serotonin-norepinephrine reuptake inhibitors 7.3.3. Selective serotonin reuptake inhibitors 7.3.4. CNS stimulants 7.3.4. Others (Benzodiazepines and miscellaneous antidepressants) 7.4. Global Depression Drugs Market Share Analysis, by Drug Class 7.5. Global Depression Drugs Market Forecast, by Drug Class 7.6. Global Depression Drugs Market Analysis, by Drug Class 8. Global Depression Drugs Market, by Disease Type 8.1. Introduction & Definition 8.2. Key Findings / Developments 8.3. Global Depression Drugs Market, by Disease Type 8.3.1. Major Depressive Disorder 8.3.2. Schizophrenia and bipolar I disorder (manic depression) 8.3.3. SSRI induced 8.3.4. Others (attention deficit hyperactivity disorder and anxiety disorders) 8.4. Global Depression Drugs Market Value Share Analysis, by Disease Type 8.5. Global Depression Drugs Market Forecast, by Disease Type 8.6. Global Depression Drugs Market Analysis, by Disease Type 9. Global Depression Drugs Market, by Distribution Channel 9.1. Introduction & Definition 9.2. Key Findings / Developments 9.3. Global Depression Drugs Market, by Distribution Channel 9.3.1. Hospital pharmacies 9.3.2. Retail pharmacies 9.3.3. Online pharmacies 9.4. Global Depression Drugs Market Share Analysis, by Distribution Channel 9.5. Global Depression Drugs Market Forecast, by Distribution Channel 9.6. Global Depression Drugs Market Analysis, by Distribution Channel 10. Global Depression Drugs Market, by Region 10.1. Global Depression Drugs Market Snapshot, by Country/Sub-region 10.2. Global Depression Drugs Market Analysis, by Region 10.2.1. North America 10.2.2. Europe 10.2.3. Asia Pacific 10.2.4. Latin America 10.2.5. Middle East & Africa 10.3. Global Depression Drugs Market Forecast, by Region 11. North America Depression Drugs Market Analysis 11.1. Policies and Regulations: U.S. 11.2. Key Findings 11.3. North America Depression Drugs Market Overview 11.4. North America Depression Drugs Market Value Share Analysis, by Drug Class 11.5. North America Depression Drugs Market Forecast, by Drug Class 11.5.1. Atypical antipsychotics 11.5.2. Serotonin-norepinephrine reuptake inhibitors 11.5.3. Selective serotonin reuptake inhibitors 11.5.4. CNS stimulants 11.5.5. Others (Benzodiazepines and miscellaneous antidepressants) 11.6. North America Depression Drugs Market Value Share Analysis, by Disease Type 11.7. North America Depression Drugs Market Forecast, by Disease Type 11.7.1. Major depressive disorder 11.7.2. Schizophrenia and bipolar I disorder (manic depression) 11.7.3. Selective serotonin reuptake inhibitors induced 11.7.4. Others (attention deficit hyperactivity disorder and anxiety disorders) 11.8. North America Depression Drugs Market Value Share Analysis, by Distribution Channel 11.9. North America Depression Drugs Market Forecast, by Distribution Channel 11.9.1. Hospital pharmacies 11.9.2. Retail pharmacies 11.9.3. Online pharmacies 11.10. North America Depression Drugs Market Value Share Analysis, by Country 11.11. North America Depression Drugs Market Forecast, by Country 11.11.1. U.S. 11.11.2. Canada 11.12. Market Trends North America 12. Europe Depression Drugs Market Analysis 12.1. Policies and Regulations: Europe 12.2. Key Findings 12.3. Europe Depression Drugs Market Overview 12.4. Europe Depression Drugs Market Value Share Analysis, by Drug Class 12.5. Europe Depression Drugs Market Forecast, by Drug Class 12.5.1. Atypical antipsychotics 12.5.2. Serotonin-norepinephrine reuptake inhibitors 12.5.3. Selective serotonin reuptake inhibitors 12.5.4. CNS stimulants 12.5.5. Others (Benzodiazepines and miscellaneous antidepressants) 12.6. Europe Depression Drugs Market Value Share Analysis, by Disease Type 12.7. Europe Depression Drugs Market Forecast, by Disease Type 12.7.1. Major depressive disorder 12.7.2. Schizophrenia and bipolar I disorder (manic depression) 12.7.3. Selective serotonin reuptake inhibitors induced 12.7.4. Others (attention deficit hyperactivity disorder and anxiety disorders) 12.8. Europe Depression Drugs Market Value Share Analysis, by Distribution Channel 12.9. Europe Depression Drugs Market Forecast, by Distribution Channel 12.9.1. Hospital pharmacies 12.9.2. Retail pharmacies 12.9.3. Online pharmacies 12.10. Europe Depression Drugs Market Value Share Analysis, by Country 12.11. Europe Depression Drugs Market Forecast, by Country 12.11.1. Germany 12.11.2. France 12.11.3. Italy 12.11.4. Spain 12.11.5. U.K. 12.11.6. Rest of Europe 12.12. Market Trends Europe 13. Asia Pacific Depression Drugs Market Analysis 13.1. Policies and Regulations: Asia Pacific 13.2. Key Findings 13.3. Asia Pacific Depression Drugs Market Overview 13.4. Asia Pacific Depression Drugs Market Value Share Analysis, by Drug Class 13.5. Asia Pacific Depression Drugs Market Forecast, by Drug Class 13.5.1. Atypical antipsychotics 13.5.2. Serotonin-norepinephrine reuptake inhibitors 13.5.3. Selective serotonin reuptake inhibitors 13.5.4. CNS stimulants 13.5.5. Others (Benzodiazepines and miscellaneous antidepressants) 13.6. Asia Pacific depression drugs Market Value Share Analysis, by Disease Type 13.7. Asia Pacific Depression Drugs Market Forecast, by Disease Type 13.7.1. Major depressive disorder 13.7.2. Schizophrenia and bipolar I disorder (manic depression) 13.7.3. Selective serotonin reuptake inhibitors induced 13.7.4. Others (attention deficit hyperactivity disorder and anxiety disorders) 13.8. Asia Pacific Depression Drugs Market Value Share Analysis, by Distribution Channel 13.9. Asia Pacific Depression Drugs Market Forecast, by Distribution Channel 13.9.1. Hospital pharmacies 13.9.2. Retail pharmacies 13.9.3. Online pharmacies 13.10. Asia Pacific Depression Drugs Market Value Share Analysis, by Country 13.11. Asia Pacific Depression Drugs Market Forecast, by Country 13.11.1. China 13.11.2. Japan 13.11.3. India 13.11.4. Australia & New Zealand 13.11.5. Rest of Asia Pacific 13.12. Market Trends Asia Pacific 14. Latin America Depression Drugs Market Analysis 14.1. Policies and Regulations: Latin America 14.2. Key Findings 14.3. Latin America Depression Drugs Market Overview 14.4. Latin America Depression Drugs Market Value Share Analysis, by Drug Class 14.5. Latin America Depression Drugs Market Forecast, by Drug Class 14.5.1. Atypical antipsychotics 14.5.2. Serotonin-norepinephrine reuptake inhibitors 14.5.3. Selective serotonin reuptake inhibitors 14.5.4. CNS stimulants 14.5.5. Others (Benzodiazepines and miscellaneous antidepressants) 14.6. Latin America depression drugs Market Value Share Analysis, by Disease Type 14.7. Latin America Depression Drugs Market Forecast, by Disease Type 14.7.1. Major depressive disorder 14.7.2. Schizophrenia and bipolar I disorder (manic depression) 14.7.3. Selective serotonin reuptake inhibitors induced 14.7.4. Others (attention deficit hyperactivity disorder and anxiety disorders) 14.8. Latin America Depression Drugs Market Value Share Analysis, by Distribution Channel 14.9. Latin America Depression Drugs Market Forecast, by Distribution Channel 14.9.1. Hospital pharmacies 14.9.2. Retail pharmacies 14.9.3. Online pharmacies 14.10. Latin America Depression Drugs Market Value Share Analysis, by Country 14.11. Latin America Depression Drugs Market Forecast, by Country 14.11.1. Brazil 14.11.2. Mexico 14.11.3. Rest of Latin America 14.12. Market Trends Latin America 15. Middle East & Africa Depression Drugs Market Analysis 15.1. Policies and Regulations: Middle East & Africa 15.2. Key Findings 15.3. Middle East & Africa Depression Drugs Market Overview 15.4. Middle East & Africa Depression Drugs Market Value Share Analysis, by Drug Class 15.5. Middle East & Africa Depression Drugs Market Forecast, by Drug class 15.5.1. Atypical antipsychotics 15.5.2. Serotonin-norepinephrine reuptake inhibitors 15.5.3. Selective serotonin reuptake inhibitors 15.5.4. CNS stimulants 15.5.5. Others (Benzodiazepines and miscellaneous antidepressants) 15.6. Middle East & Africa Depression Drugs Market Value Share Analysis, by Disease Type 15.7. Middle East & Africa Depression Drugs Market Forecast, by Disease Type 15.7.1. Major depressive disorder 15.7.2. Schizophrenia and bipolar I disorder (manic depression) 15.7.3. Selective serotonin reuptake inhibitors induced 15.7.4. Others (attention deficit hyperactivity disorder and anxiety disorders) 15.8. Middle East & Africa Depression Drugs Market Value Share Analysis, by Distribution Channel 15.9. Middle East & Africa Depression Drugs Market Forecast, by Distribution Channel 15.9.1. Hospital pharmacies 15.9.2. Retail pharmacies 15.9.3. Online pharmacies 15.10. Middle East & Africa Depression Drugs Market Value Share Analysis, by Country 15.11. Middle East & Africa Depression Drugs Market Forecast, by Country 15.11.1. GCC 15.11.2. South Africa 15.11.3. Israel 15.11.4. Rest of Middle East & Africa 15.12. Market Trends Middle East & Africa 16. Competition Landscape 16.1. Competition Matrix 16.2. Depression Drugs Market Share Analysis, by Company 16.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy) 16.3.1. Otsuka Pharmaceutical Co., Ltd. 16.3.1.1. Company Description 16.3.1.2. Financial Overview 16.3.1.3. Recent Developments 16.3.1.4. Strategic Overview 16.3.1.4. SWOT Analysis 16.3.2. Eli Lilly and Company 16.3.2.1. Company Description 16.3.2.2. Financial Overview 16.3.2.3. Strategic Overview 16.3.2.4. SWOT Analysis 16.3.3. Pfizer, Inc. 16.3.3.1. Company Description 16.3.3.2. Financial Overview 16.3.3.3. Strategic Overview 16.3.3.4. SWOT Analysis 16.3.4. AstraZeneca plc. 16.3.4.1. Company Description 16.3.4.2. Financial Overview 16.3.4.3. SWOT Analysis 16.3.5. Novartis AG 16.3.5.1. Company Description 16.3.5.2. Financial Overview 16.3.5.3. Strategic Overview 16.3.5.4. SWOT Analysis 16.3.6. GlaxoSmithKline plc 16.3.6.1. Company Description 16.3.6.2. Financial Overview 16.3.6.3. Strategic Overview 16.3.6.4. Recent Developments 16.3.6.5. SWOT Analysis 16.3.7. Takeda Pharmaceutical Company Ltd 16.3.7.1. Company Description 16.3.7.2. Financial Overview 16.3.7.3. Strategic Overview 16.3.7.4. SWOT Analysis 16.3.8. Sebela Pharmaceutical Inc. 16.3.8.1. Company Description 16.3.8.2. Financial Overview 16.3.8.3. Strategic Overview 16.3.8.3. SWOT Analysis 16.3.9. Allergan USA, Inc. 16.3.9.1. Company Description 16.3.9.2. Financial Overview 16.3.9.3. Strategic Overview 16.3.9.3. SWOT Analysis 16.3.10. Johnson & Johnson 16.3.10.1. Company Description 16.3.10.2. Financial Overview 16.3.10.3. Strategic Overview 16.3.10.4. SWOT Analysis
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Opportunity Map, by Drug Class, 2021
Table 02: Opportunity Map, by Disease Type, 2021
Table 03: Opportunity Map, by Distribution Channel, 2021
Table 04: Global Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2021–2031
Table 05: Global Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031
Table 06: Global Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031
Table 07: Global Depression Drugs Market (US$ Mn) Forecast, by Region, 2020–2031
Table 08: North America Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031
Table 09: North America Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031
Table 10: North America Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031
Table 11: North America Depression Drugs Market Size (US$ Mn) Forecast, by Country, 2020–2031
Table 12: U.S. Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031
Table 13: U.S. Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031
Table 14: U.S. Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031
Table 15: Canada Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031
Table 16: Canada Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031
Table 17: Canada Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031
Table 18: Europe Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031
Table 19: Europe Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031
Table 20: Europe Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031
Table 21: Europe Depression Drugs Market Size (US$ Mn) Forecast, by Country, 2020–2031
Table 22: Germany Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031
Table 23: Germany Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031
Table 24: Germany Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031
Table 25: France Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031
Table 26: France Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031
Table 27: France Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031
Table 28: Italy Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031
Table 29: Italy Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031
Table 30: Italy Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031
Table 31: Spain Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031
Table 32: Spain Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031
Table 33: Spain Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031
Table 34: U.K. Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031
Table 35: U.K. Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031
Table 36: U.K. Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031
Table 37: Rest of Europe Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031
Table 38: Rest of Europe Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031
Table 39: Rest of Europe Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031
Table 40: Asia Pacific Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031
Table 41: Asia Pacific Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031
Table 42: Asia Pacific Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031
Table 43: Asia Pacific Depression Drugs Market Size (US$ Mn) Forecast, by Country, 2020–2031
Table 44: China Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031
Table 45: China Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031
Table 46: China Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031
Table 47: Japan Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031
Table 48: Japan Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031
Table 49: Japan Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031
Table 50: India Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031
Table 51: India Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031
Table 52: India Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031
Table 53: Australia & New Zealand Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031
Table 54: Australia & New Zealand Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031
Table 55: Australia & New Zealand Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031
Table 56: Rest of Asia Pacific Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031
Table 57: Rest of Asia Pacific Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031
Table 58: Rest of Asia Pacific Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031
Table 59: Latin America Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031
Table 60: Latin America Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031
Table 61: Latin America Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031
Table 62: Latin America depression drugs Market Size (US$ Mn) Forecast, by Country, 2020–2031
Table 63: Brazil Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031
Table 64: Brazil Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031
Table 65: Brazil Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031
Table 66: Mexico Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031
Table 67: Mexico Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031
Table 68: Mexico Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031
Table 69: Rest of Latin America Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031
Table 70: Rest of Latin America Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031
Table 71: Rest of Latin America Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031
Table 72: Middle East & Africa depression drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031
Table 73: Middle East & Africa depression drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031
Table 74: Middle East & Africa depression drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031
Table 75: Middle East & Africa depression drugs Market Size (US$ Mn) Forecast, by Country, 2020–2031
Table 76: GCC Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031
Table 77: GCC Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031
Table 78: GCC Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031
Table 79: South Africa Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031
Table 80: South Africa Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031
Table 81: South Africa Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031
Table 82: Israel Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031
Table 83: Israel Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031
Table 84: Israel Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031
Table 85: Rest of Middle East & Africa Depression Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020–2031
Table 86: Rest of Middle East & Africa Depression Drugs Market Size (US$ Mn) Forecast, by Disease Type, 2020–2031
Table 87: Rest of Middle East & Africa Depression Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2020–2031
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Depression Drugs Market Size (US$ Mn), by Drug Class, 2021 (A)
Figure 02: Global Depression Drugs Market Revenue (%), 2021 (A)
Figure 03: Global Depression Drugs Market Size (US$ Mn) Forecast, 2020–2031
Figure 04: Market Value Share, by Drug Class (2021)
Figure 05: Market Value Share, by Disease Type (2021)
Figure 06: Market Value Share, by Distribution Channel (2021)
Figure 07: Market Value Share, by Region (2021)
Figure 08: Global Depression Drugs Market Value Share, by Valence, 2021 and 2031
Figure 09: Global Depression Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Atypical antipsychotics, 2021–2031
Figure 10: Global Depression Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by SNRI, 2021–2031
Figure 11: Global Depression Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by SSRI, 2021–2031
Figure 12: Global Depression Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by CNS stimulants, 2021–2031
Figure 13: Global Depression Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2021–2031
Figure 14: Global Depression Drugs Market Value Share, by Disease Type, 2021 and 2031
Figure 15: Global Depression Drugs Market Revenue (US$ Mn), by MDD, 2021–2025
Figure 16: Global Depression Drugs Market Revenue (US$ Mn), by Schizophrenia and bipolar I disorder, 2021–2025
Figure 17: Global Depression Drugs Market Revenue (US$ Mn), by SSRI induced, 2020–2031
Figure 18: Global Depression Drugs Market Revenue (US$ Mn), by Others, 2020–2031
Figure 19: Global Depression Drugs Market Value Share, by Distribution Channel, 2021 and 2031
Figure 20: Global Depression Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital pharmacies, 2020–2031
Figure 21: Global Depression Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail pharmacies, 2020–2031
Figure 22: Global Depression Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online pharmacies, 2020–2031
Figure 23: Global Depression Drugs Market Analysis, by Region, 2021 and 2031
Figure 24: North America Depression Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020–2031
Figure 25: North America Depression Drugs Market Value Share, by Drug Class, 2021 and 2031
Figure 26: North America Depression Drugs Market Value Share, by Disease Type, 2021 and 2031
Figure 27: North America Depression Drugs Market Value Share, by Distribution Channel, 2021 and 2031
Figure 28: North America Depression Drugs Market Value Share, by Country, 2021 and 2031
Figure 29: Europe Depression Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020–2031
Figure 30: Europe Depression Drugs Market Value Share, by Drug Class, 2021 and 2031
Figure 31: Europe Depression Drugs Market Value Share, by Disease Type, 2021 and 2031
Figure 32: Europe Depression Drugs Market Value Share, by Distribution Channel, 2021 and 2031
Figure 33: Europe Depression Drugs Market Value Share, by Country/Sub Region, 2021 and 2031
Figure 34: Asia Pacific Depression Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020–2031
Figure 35: Asia Pacific Depression Drugs Market Value Share, by Drug Class, 2021 and 2031
Figure 36: Asia Pacific Depression Drugs Market Value Share, by Disease Type, 2021 and 2031
Figure 37: Asia Pacific Depression Drugs Market Value Share, by Distribution Channel, 2021 and 2031
Figure 38: Asia Pacific Depression Drugs Market Value Share, by Country/Sub Region, 2021 and 2031
Figure 39: Latin America depression drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020–2031
Figure 40: Latin America Depression Drugs Market Value Share, by Drug Class, 2021 and 2031
Figure 41: Latin America Depression Drugs Market Value Share, by Disease Type, 2021 and 2031
Figure 42: Latin America Depression Drugs Market Value Share, by Distribution Channel, 2021 and 2031
Figure 43: Latin America Depression Drugs Market Value Share, by Country, 2021 and 2031
Figure 44: Middle East & Africa Depression Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020–2031
Figure 45: Middle East & Africa Depression Drugs Market Value Share, by Drug Class, 2021 and 2031
Figure 46: Middle East & Africa Depression Drugs Market Value Share, by Disease Type, 2021 and 2031
Figure 47: Middle East & Africa Depression Drugs Market Value Share, by Distribution Channel, 2021 and 2031
Figure 48: Middle East & Africa Depression Drugs Market Value Share, by Country/Sub Region, 2021 and 2031
Figure 49: Depression Drugs Sales Analysis, 2016–2020
Figure 50: Depression Drugs Market Share, by Company, 2021
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the current global market worth for depression drugs?
The global depression drugs market is currently worth more than US$ 13 Bn.
What was the last 5 year’s market CAGR for the sales of depression drugs?
From 2016-2020, the market for depression drugs increased at around 1% CAGR.
What are key trends likely to influence sales of depression drugs?
Rise in prevalence of depression and growing geriatric population are major factors driving growth of the market.
Who are the prominent manufacturers of depression drugs?
Key depression drug suppliers are Johnson and Johnson, Sebela Pharmaceutical Inc., Takeda Pharmaceutical Company Ltd., GlaxoSmithKline, and Novartis AG.
Which region is most attractive for depression drug vendors?
With 40% share, North America will largely contribute to the growth of depression drugs revenue.
How lucrative is the opportunity for market expansion in Germany?
Sales of antidepressants in Germany are expected to rise at a CAGR of 1% over the forecast period of 2021 to 2031.
Which drug class has the largest share in the market for depression drugs?
Serotonin-norepinephrine reuptake inhibitors (SNRIs) account for a share of 60% in the market.
Which are the top 5 countries driving demand for depression drugs?
The U.S., China, U.K, Germany, and France are expected to drive most of the demand for depression drugs.
Which distribution channel is expected to hold the highest share for the sales for depression drugs?
Online pharmacies are expected to hold more than 40% market share for depression drugs.
What is the predicted expansion rate for the market over the next ten years?
The global market is expected to expand at a CAGR of 4% over the forecast period of 2021 to 2031.
Depression Drugs Market